# Ivermectin Combined With Immune Checkpoint Inhibition in Cancer (ICONIC)

> **NCT07487805** · PHASE2 · NOT_YET_RECRUITING · sponsor: **University of Florida** · enrollment: 80 (estimated)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **DRUG:** Intermediate-dose ivermectin
- **DRUG:** High-dose ivermectin

## Key facts

- **NCT ID:** NCT07487805
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2027-07
- **Final completion:** 2027-10
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07487805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07487805, "Ivermectin Combined With Immune Checkpoint Inhibition in Cancer (ICONIC)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07487805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*